Short Communication

Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptor-binding domain (RBD)

Giovanni Ribaudoa, Paolo Coghi, Li Jun Yangd, Jerome P. L. Ngd, Andrea Mastinua, Maurizio Memoa, Vincent Kam Wai Wongd and Alessandra Gianoncellia

aDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; bSchool of Pharmacy, Macau University of Science and Technology, Taipa, Macau, China; cState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macau, China; dNeher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macau, China

Abstract

The mechanism of host cell invasion of severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 is connected with the interaction of spike protein (S) with angiotensin-converting enzyme 2 (ACE2) through receptor-binding domain (RBD). Small molecules targeting this assembly are being investigated as drug candidates to contrast SARS-CoV-2. In this context, chloroquine, an antimalarial agent proposed as a repurposed drug to treat coronavirus disease-19 (COVID-19), was hypothesized to bind RBD among its other mechanisms. Similarly, artemisinin and its derivatives are being studied as potential antiviral agents. In this work, we investigated the interaction of artemisinin, its metabolite dihydroartemisinin and chloroquine with RBD by means of computational tools and in vitro. Docking studies showed that the compounds interfere with the same region of the protein and molecular dynamics (MD) simulations demonstrated the stability of the predicted complexes. Bio-layer interferometry showed that chloroquine dose-dependently binds RBD (KD = 35.9 μM) more efficiently than artemisinins.

Article History

Received 17 March 2021
Accepted 1 May 2021

Keywords

SARS-CoV-2; artemisinin; spike protein; molecular dynamics; bio-layer interferometry

Contact

Giovanni Ribaudo giovanni.ribaudo@unibs.it; Paolo Coghi coghips@must.edu.mo

Supplemental data for this article can be accessed online at https://doi.org/10.1080/14786419.2021.1925894.
1. Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein (S) mediates cellular invasion by interfering with angiotensin-converting enzyme 2 (ACE2) through its receptor-binding domain (RBD, residues 331-524 of S1 subunit, Figure 1A) (Tai et al. 2020; Wrapp et al. 2020). Targeting this assembly with small molecules, peptides and antibodies emerged as a possible intervention strategy to contrast infection (Al Adem et al. 2020; Xiu et al. 2020; Chen et al. 2021). The antimalarial agent chloroquine is thought to be active against SARS-CoV-2 through a combination of mechanisms, such as the inhibition endocytic pathways by elevation of endosomal pH and the interference with glycosylation of ACE2 (Vincent et al. 2005; Mauthe et al. 2018; Gendrot et al. 2020). Moreover, computational evidences suggested that chloroquine could also directly interfere with S or ACE2 proteins (Fantini et al. 2020; Badraoui et al. 2021). The efficacy of chloroquine is a debated issue. Nevertheless, it can block the binding of SARS-CoV-2 to ACE2 in vitro (Wang et al. 2020). On similar basis, other antimalarial agents such as artemisinins demonstrated in vitro inhibition of SARS-CoV-2 (Krishna et al. 2021; Kavak et al. 2021). Extracts from the sweet woodworm Artemisia annua have been used for centuries in Chinese traditional medicine for treating the symptoms of febrile diseases, tidal fever and summer heat stroke (Brown 2010). In particular, a compound isolated from this plant and known as “qinghaosu”, which was later renamed artemisinin, was tested in patients together with its derivatives between 1970s and 1980s for its activity against malaria (Aweeka and German 2008). From a chemical point of view, artemisinin is a sesquiterpene lactone containing a peroxide bridge (Nahar et al. 2020). Derivatives such as artesunate, artemether and arteether have been used in clinic against malaria for decades (Aweeka and German 2008). Moreover, artemisinins are being investigated to treat diseases such as cancer, inflammatory conditions, immunosuppression and viral or fungal infections (Ho et al. 2014; Coghi et al. 2018).
2. Results and discussion

Concerning their antiviral application, artemisinins have been extensively studied as potential remedies against herpes and hepatitis B and C viruses (Ho et al. 2014). As anticipated, artemisinins possess several pharmacological properties, and different mechanisms, such as anti-inflammatory action, reduction of nucleoprotein production or inhibition of viral RNA and proteins at post-entry step, may be involved in their antiviral effect, also in the case of SARS-CoV-2 (Cao et al. 2020; Kshirsagar and Rao 2021). The current study focuses on the investigation of the direct effect of artemisinin and dihydroartemisinin on S protein RBD. Computational techniques, including docking and molecular dynamics (MD) simulations, were adopted to study the structural details and the stability of the RBD-ligand complexes (Figure 1B). Moreover, the binding was tested in vitro by Bio-layer interferometry, a label-free technology for measuring biomolecular interactions.

Most of previous contributions investigated the docking of small molecules to RBD focusing on the interface with ACE2 (Rathod et al. 2020), but the presence of other sites also emerged (Alexpandi et al. 2020; Basu et al. 2020). Accordingly, binding

![Figure 1. Spike protein trimer, with one of the RBDs rotated up and highlighted (PDB ID: 6VSB, A); chemical structures of the studied compounds (B); predicted interaction patterns with RBD of chloroquine (red, $-5.6$ kcal/mol), artemisinin (green, $-7.0$ kcal/mol) and dihydroartemisinin (blue, $-6.5$ kcal/mol, C).](image-url)
surface analysis showed the presence of 3 putative ligand interaction sites on RBD (Figure S1 in the Supplementary Material). As previously observed in studies carried out on a structure obtained by homology modeling, docking highlighted artemisinin as the most promising ligand of the set (Figure 1C, see Supplementary Material for docking protocol) (Prashantha et al. 2021). The predicted binding models show that the compounds interact with the same region of RBD (Figure S2 in the Supplementary Material).

MD studies were enrolled to further investigate the stability of complexes (Doerr et al. 2016, Gianoncelli et al. 2020). In particular, 25 ns MD simulations on RBD-artemisinin, RBD-dihydroartemisinin and RBD-chloroquine docked models were carried out and root mean square deviation (RMSD) trajectory were compared. In all cases, the complexed protein backbones reached stabilization within less than 5 ns of simulation time: RMSD values (average ± standard deviation) of 2.51 ± 0.24 Å, 2.15 ± 0.18 Å and 2.33 ± 0.14 Å were measured for backbones of RBD-artemisinin, RBD-dihydroartemisinin and RBD-chloroquine complexes, respectively. Greater difference was observed on the behavior of the ligands. In the RBD-chloroquine complex, the ligand reached stabilization after 7 ns and showed limited fluctuation throughout the remaining simulation time, in which the compound was retained within the binding site (average RMSD = 8.62 ± 2.97 Å). Similarly, dihydroartemisinin reached stabilization after 3 ns (average RMSD = 5.23 ± 0.76 Å). On the other hand, greater vibrations were observed for artemisinin, in particular in the 0-20 ns simulation timeframe, and the compound reached stabilization only in the final 5 ns of simulation (Figure S3 in the Supplementary Material).

The binding of chloroquine, artemisinin and dihydroartemisinin was then experimentally investigated using Bio-layer interferometry. This analysis relies on the immobilization of RBD to the biosensor surface with subsequent exposure to different ligand concentration, allowing the real-time measurement of association and dissociation phases (see Supplementary Material for experimental details). Chloroquine dose-dependently binds RBD ($K_D = 35.9 \mu M$, $R^2 = 0.9827$) more tightly than artemisinin ($K_D = 51.4 \mu M$, $R^2 = 0.6264$), while dihydroartemisinin showed weaker binding and worse correlation ($K_D = 66.5 \mu M$, $R^2 = 0.5210$). Kinetic parameters, such as association rate ($k_{on}$) and dissociation rate ($k_{off}$) for these complexes are reported in the Supplementary Material (Figures S4–S6). Since ACE2 is the macromolecular interactor of RBD and small molecules interfering with such receptor could contrast viral infection (Bourgonje et al. 2020), binding of studied compounds was also measured towards ACE2. Although, no notable interaction was detected for chloroquine, artemisinin and dihydroartemisinin under these experimental conditions (Figures S7 and S8 in the Supplementary Material).

3. Conclusions

While docking studies suggested that artemisinin would have been the most promising binder for RBD, Bio-layer interferometry highlighted chloroquine as the best ligand of the set. Consistently, MD simulations confirmed that chloroquine forms a stable complex with RBD, as lower fluctuation values were measured for this assembly. The
results of this study support the hypothesis that “artemisinin” may act through a combination of mechanisms when exploiting their antiviral function, and suggest that RBD, rather than ACE2, could be one of the macromolecular targets for contrasting cellular invasion by SARS-CoV-2.

Disclosure statement
The authors declare no conflict of interest.

Funding
This work was granted from the University of Brescia and Macau University of Science and Technology, thanks to FDCT grant from the Macao Science and Technology Development Fund (Project code: 0096/2020/A).

References
Al Adem K, Shanti A, Stefanini C, Lee S. 2020. Inhibition of SARS-CoV-2 entry into host cells using small molecules. Pharmaceuticals (Basel). 13(12):447.
Alexpandi R, De Mesquita JF, Pandian SK, Ravi AV. 2020. Quinolines-based SARS-CoV-2 3CLpro and RdRp inhibitors and spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico. Anal Front Microbiol. 11(1796). PMID: 32793181 PMCID: PMC7390959 DOI: 10.3389/fmicb.2020.01796
Aweeka FT, German PI. 2008. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet. 47(2):91–102.
Badraoui R, Adnan M, Bardakci F, Alreshidi MM. 2021. Chloroquine and hydroxychloroquine interact differently with ACE2 domains reported to bind with the coronavirus spike protein: mediation by ACE2 polymorphism. Molecules. 26(3):673.
Basu A, Sarkar A, Maulik U. 2020. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. Sci Rep. 10(1):17699.
Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, et al. 2020. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 251(3):228–248.
Brown GD. 2010. The biosynthesis of Artemisinin (Qinghaosu) and the phytochemistry of Artemisia annua L. (Qinghao). Molecules. 15(11):7603–7698.
Cao R, Hu H, Li Y, Wang X, Xu M, Liu J, Zhang H, Yan Y, Zhao L, Li W, et al. 2020. Anti-SARS-CoV-2 Potential of Artemisinins in vitro. ACS Infect Dis. 6(9):2524–2531.
Chen RH, Yang LJ, Hamdoun S, Chung SK, Lam CW, Zhang KX, Guo X, Xia C, Law BYK, Wong VKW. 2021. 1,2,3,4,6-Pentagalloyl glucose, a RBD-ACE2 binding inhibitor to prevent SARS-CoV-2 infection. Front Pharmacol. 12:634176.
Coghi P, Yaremenko IA, Prommana P, Radulov PS, Syroeshkin MA, Wu YJ, Gao JY, Gordillo FM, Mok S, Wong VKW, et al. 2018. Novel peroxides as promising anticancer agents with unexpected depressed antimalarial Activity. ChemMedChem. 13(9):902–908.
Doerr S, Harvey MJ, Noé F, De Fabritiis G. 2016. HTMD: high-throughput molecular dynamics for molecular discovery. J Chem Theory Comput. 12(4):1845–1852.
Fantini J, Di Scala C, Chahinian H, Yahi N. 2020. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 55(S):105960.
Gendrot M, Andreani J, Boxberger M, Jardot P, Fonta I, Le Bideau M, Duflot I, Mosnier J, Rolland C, Bogreau H, et al. 2020. Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. Travel Med Infect Dis. 37:101873.

Gianoncelli A, Ongaro A, Zagotto G, Memo M, Ribaud G. 2020. 2-(3,4-Dihydroxyphenyl)-4-(2-(4-nitrophenyl)hydrazono)-4H-chromene-3,5,7-triol. Molbank. 2020(3):M1144.

Ho WE, Peh HY, Chan TK, Wong WSF. 2014. Artemisinins: pharmacological actions beyond antimalarial. Pharmacol Ther. 142(1):126–139.

Kavak E, Mutlu D, Ozok O, Arslan S, Kivrak A. 2021. Design, synthesis and pharmacological evaluation of novel Artemisinin-thymol. Nat Prod Res. PMID: 33416016. doi:10.1080/14786419.2020.1865954.

Krishna S, Augustin Y, Wang J, Xu C, Staines HM, Platteeuw H, Kamarulzaman A, Sall A, Kremsner P. 2021. Repurposing antimalarials to tackle the COVID-19 pandemic. Trends Parasitol. 37(1):8–11.

Kshirsagar SG, Rao RV. 2021. Antiviral and immunomodulation effects of Artemisia. Medicina (Kaunas). 57(3):217.

Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, Coppes RP, Engedal N, Mari M, Reggiori F. 2018. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 14(8):1435–1455.

Nahar L, Guo M, Sarker SD. 2020. A review on the latest advances in extraction and analysis of artemisinin. Phytochem Anal. 31(1):5–14.

Prashanthan CN, Gouthami K, Lavanya L, Bhavanam S, Jakhar A, Shakthiraju RG, Suraj V, Sahana KV, Sujana HS, Guruprasad NM, et al. 2021. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. J Mol Graph Model. 102:107769.

Rathod SB, Prajapati PB, Punjabi LB, Prajapati KN, Chauhan N, Mansuri MF. 2020. Peptide modeling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2. In Silico Pharmacol. 8(1):3.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. 2020. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 17(6):613–620.

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. 2005. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2:69.

Wang N, Han S, Liu R, Meng L, He H, Zhang Y, Wang C, Lv Y, Wang J, Li X, et al. 2020. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. Phytomedicine. 79:153333.

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 367(6483):1260–1263.

Xiu S, Dick A, Ju H, Mirzaie S, Abdi F, Cocklin S, Zhan P, Liu X. 2020. Inhibitors of SARS-CoV-2 entry: current and future opportunities. J Med Chem. 63(21):12256–12274.